Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jun;69(6):1111–1114. doi: 10.1038/bjc.1994.218

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

A Ravaud 1, S Négrier 1, L Cany 1, Y Merrouche 1, M Le Guillou 1, J Y Blay 1, M Clavel 1, R Gaston 1, R Oskam 1, T Philip 1
PMCID: PMC1969444  PMID: 8198979

Abstract

A double-institution phase II study was performed in patients with metastatic renal cell carcinoma treated subcutaneously (s.c.) with interleukin 2 (IL-2) and alpha-interferon (INF-alpha). Thirty-eight patients were treated over a course of 7 weeks. Initially (day 1 + 2) patients received s.c. IL-2 at 18 x 10(6) IU m-2. During the following 6 weeks, patients received s.c. IL-2 at 3.6 x 10(6) IU m-2 for 5 days per week and s.c. INF-alpha at 5 x 10(6) for 3 days per week. Thirty-eight patients were evaluated for response. An objective response was seen in seven patients (18.4 +/- 12.3%), with one complete response and six partial responses. Median duration of response was 6.7 months. Toxicity could be evaluated in 38 patients and was limited. Mild to moderate toxicity included fever (97%), fatigue or malaise (76%), nausea or vomiting (50%), anorexia (32%), hypotension (26%), neurological disturbances (26%) and hypercreatininaemia (39%). In addition, four grade IV haematological toxicities were noted. No cardiac side-effects were seen. IL-2 and INF-alpha given by this schedule can be safely administered in an outpatient setting. The objective response rate was similar to our previous treatments with high-dose IL-2 given as a continuous infusion.

Full text

PDF
1111

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Körfer A., Evers P., Franks C. R., Knüver-Hopf J., Lopez-Hänninen E., Fischer M., Mohr H., Dallmann I., Hadam M. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother. 1990 Mar;2(1):18–26. [PubMed] [Google Scholar]
  2. Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  3. Atzpodien J., Poliwoda H., Kirchner H. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol. 1991 Oct;18(5 Suppl 7):108–112. [PubMed] [Google Scholar]
  4. Cameron R. B., McIntosh J. K., Rosenberg S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res. 1988 Oct 15;48(20):5810–5817. [PubMed] [Google Scholar]
  5. Dillman R. O., Oldham R. K., Tauer K. W., Orr D. W., Barth N. M., Blumenschein G., Arnold J., Birch R., West W. H. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991 Jul;9(7):1233–1240. doi: 10.1200/JCO.1991.9.7.1233. [DOI] [PubMed] [Google Scholar]
  6. Elson P. J., Witte R. S., Trump D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988 Dec 15;48(24 Pt 1):7310–7313. [PubMed] [Google Scholar]
  7. Fisher R. I., Coltman C. A., Jr, Doroshow J. H., Rayner A. A., Hawkins M. J., Mier J. W., Wiernik P., McMannis J. D., Weiss G. R., Margolin K. A. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988 Apr;108(4):518–523. doi: 10.7326/0003-4819-108-4-518. [DOI] [PubMed] [Google Scholar]
  8. Lotze M. T., Matory Y. L., Rayner A. A., Ettinghausen S. E., Vetto J. T., Seipp C. A., Rosenberg S. A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986 Dec 15;58(12):2764–2772. doi: 10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  9. Margolin K. A., Rayner A. A., Hawkins M. J., Atkins M. B., Dutcher J. P., Fisher R. I., Weiss G. R., Doroshow J. H., Jaffe H. S., Roper M. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989 Apr;7(4):486–498. doi: 10.1200/JCO.1989.7.4.486. [DOI] [PubMed] [Google Scholar]
  10. Palmer P. A., Atzpodien J., Philip T., Negrier S., Kirchner H., Von der Maase H., Geertsen P., Evers P., Loriaux E., Oskam R. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother. 1993 Summer;8(2):123–136. doi: 10.1089/cbr.1993.8.123. [DOI] [PubMed] [Google Scholar]
  11. Palmer P. A., Vinke J., Philip T., Negrier S., Atzpodien J., Kirchner H., Oskam R., Franks C. R. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 1992 Jun;3(6):475–480. doi: 10.1093/oxfordjournals.annonc.a058239. [DOI] [PubMed] [Google Scholar]
  12. Quesada J. R., Rios A., Swanson D., Trown P., Gutterman J. U. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985 Nov;3(11):1522–1528. doi: 10.1200/JCO.1985.3.11.1522. [DOI] [PubMed] [Google Scholar]
  13. Ravaud A., Negrier S., Lakdja F., Mercatello A., Cany L., Coronel B., Ranchere J. Y., Bécouarn Y., Bui B. N., Philip T. Effets secondaires de l'interleukine 2. Bull Cancer. 1991 Nov;78(11):989–1005. [PubMed] [Google Scholar]
  14. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  15. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rosenberg S. A., Lotze M. T., Yang J. C., Linehan W. M., Seipp C., Calabro S., Karp S. E., Sherry R. M., Steinberg S., White D. E. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989 Dec;7(12):1863–1874. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  17. Siegel J. P., Puri R. K. Interleukin-2 toxicity. J Clin Oncol. 1991 Apr;9(4):694–704. doi: 10.1200/JCO.1991.9.4.694. [DOI] [PubMed] [Google Scholar]
  18. Sleijfer D. T., Janssen R. A., Buter J., de Vries E. G., Willemse P. H., Mulder N. H. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992 Jul;10(7):1119–1123. doi: 10.1200/JCO.1992.10.7.1119. [DOI] [PubMed] [Google Scholar]
  19. Stein R. C., Malkovska V., Morgan S., Galazka A., Aniszewski C., Roy S. E., Shearer R. J., Marsden R. A., Bevan D., Gordon-Smith E. C. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]. Br J Cancer. 1991 Feb;63(2):275–278. doi: 10.1038/bjc.1991.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  21. Whitehead R. P., Ward D., Hemingway L., Hemstreet G. P., 3rd, Bradley E., Konrad M. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res. 1990 Oct 15;50(20):6708–6715. [PubMed] [Google Scholar]
  22. von der Maase H., Geertsen P., Thatcher N., Jasmin C., Mercatello A., Fosså S. D., Symann M., Stoter G., Nagel G., Israel L. Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study. Eur J Cancer. 1991;27(12):1583–1589. doi: 10.1016/0277-5379(91)90419-e. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES